Duoblock 5/20 tablet

Indications:

Duoblock tablet is indicated for the treatment of hypertension, alone or with other antihypertensive agents. Duoblock tablet may also be used as initial therapy in patients who are likely to need multiple antihypertensive agents to achieve their blood pressure goals.

Dosage & Administrations:

Initial Therapy: The usual starting dose of Amlodipine and Olmesartan combination tablet is 5/20 mg once daily. The dose can be increased after 1 to 2 weeks of therapy to a maximum dose of one 10/40 mg tablet once daily as needed to control blood pressure. Initial therapy with this combination product is not recommended in patients >75 years old or with hepatic impairment. Amlodipine and Olmesartan combination tablet may be taken with or without food. Amlodipine and Olmesartan combination tablet may be administered with other antihypertensive agents.
Replacement Therapy: Amlodipine and Olmesartan combination tablet may be substituted for its individually titrated components. When substituting for individual components, the dose of one or both of the components can be increased if blood pressure control has not been satisfactory.
Add-on Therapy: Amlodipine and Olmesartan combination tablet may be used to provide additional blood pressure lowering for patients not adequately controlled with amlodipine (or another dihydropyridine calcium channel blocker) alone or with olmesartan medoxomil (or another angiotensin receptor blocker) alone.

Side effects:

The overall incidence of adverse reactions on therapy with Amlodipine and Olmesartan combination tablet was similar to that seen with corresponding doses of the individual components of this combination product, and to placebo. The reported adverse reactions were generally mild and seldom led to discontinuation of treatment (2.6% for Amlodipine and Olmesartan combination tablet and 6.8% for placebo). These included hypotension, orthostatic hypotension, rash, pruritus, palpitation, urinary frequency, and nocturia. Edema is a known, dose-dependent adverse effect of amlodipine but not of olmesartan medoxomil.